An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | MicrobiomeTrials← Back to trialsNCT05798117
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-02-28Est. Completion: 2026-09-24
Enrollment target: 21 participants Locations- Novartis Investigative Site, Clayton, Victoria, Australia
- Novartis Investigative Site, Paris, France
- Novartis Investigative Site, Pessac, France
- Novartis Investigative Site, Strasbourg, France
- Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Novartis Investigative Site, Mainz, Germany
- Novartis Investigative Site, Barcelona, Spain
- Novartis Investigative Site, Madrid, Spain
- Novartis Investigative Site, Bern, Switzerland
- Novartis Investigative Site, Lausanne, Switzerland
Other microbiome trials you might be interested in
Systemic Lupus Erythematosus
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-s…
Birmingham, United StatesEst. completion Aug 22, 2025
Systemic Lupus Erythematosus (SLE)
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic…
Phoenix, United StatesCompleted Mar 29, 2030
Phase 2
Recruiting
Cutaneous Lupus Erythematosus (CLE)Systemic Lupus ErythematosusSLESLE (Systemic Lupus)CLE
The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) …
Beverly Hills, United StatesEst. completion Jul 2026